Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate
Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Risedronate Daily or Weekly
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 1P1
- Louis-Georges Ste-Marie, MD
-
-
-
-
California
-
Palm Desert, California, United States, 92260
- Maria Greenwald, MD
-
-
Colorado
-
Lakewood, Colorado, United States, 80227
- Paul Miller, MD
-
-
Georgia
-
Decatur, Georgia, United States, 30033
- Grattan Woodson, MD
-
Gainesville, Georgia, United States, 30501
- Christopher Recknor, MD
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
- Robert Recker, MD
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Nelson Watts, MD
-
-
Pennsylvania
-
Wyomissing, Pennsylvania, United States, 19610
- Ronald D Emkey, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Completed month 36 of Study RVN-008993.
- Underwent an iliac crest bone biopsy at month 36.
Exclusion Criteria:
- Was less than 60% compliant with regard to taking study drug from the start of the study drug to month 24 of study RVN-008993.
Study Plan
How is the study designed?
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
1
Women taking risedronate for 5 years
|
risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Differences in iliac crest bone histomorphometry and bone quality in patients receiving risedronate
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Ana M Balske, MD, Procter and Gamble
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Musculoskeletal Diseases
- Bone Diseases
- Bone Diseases, Metabolic
- Osteoporosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Risedronic Acid
Other Study ID Numbers
Other Study ID Numbers
- 2004140
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.